Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. Thus, it is recommended that live-virus vaccines should be administered the same day or ≥4 weeks apart. Data on co-administration of the currently available whole-cell killed Oral Cholera Vaccine (OCVs) with other oral vaccines, specifically, oral polio vaccines (OPV) is lacking. Although the risk of immunological interference due to co-administration of live vaccines with non-live vaccines is considered small if at all, a theoretical concern of interference has been raised. Given the substantial geographic correlation between polio- and cholera-affected and at-risk areas, which include some of the world's most impoverished and hard-to-reach populations, a strategy of co-administration of OCV with OPV to children targeted to receive OPVs has the potential to optimize the use of limited resources and improve coverage for both vaccines. The manufacturer recommendation for a two-week interval between administration of OPV and OCV precludes an integrated campaign or routine use in which OCV could be co-administered with OPV.
Stanford is currently accepting patients for this trial.
Intervention(s):
- biological: Oral Polio Vaccine
- biological: Oral Cholera Vaccine
Eligibility
Inclusion Criteria:
- Apparently healthy children aged 1 to 3 years of age. Family able to understand and
comply with planned study procedures and consents to be in the study.
- Have received either no dose or only one dose of OPV ( 0 - 1 dose) and has not
received any dose of IPV or OCV at any time before enrollment based upon immunization
card record or history from parents.
Exclusion Criteria:
- Parents and children who are unable / unwilling to participate in the full length of
the study for any reason.
- Child / family planning on moving away from the study area during the study period
- A diagnosis, suspicion of, or clinical condition consistent with an immunodeficiency
disorder (either in the child or in a member of the immediate family) or is on
long-term (>3 months) of immunosuppressive therapy.
- A suspicion or known history of bleeding disorder that would contraindicate
venipuncture.
- Acute diarrhea, infection or illness at the time of the first visit that would require
the child's admission to a hospital or would contraindicate provision of OPV per
country guidelines.
- History of severe allergic reaction to component of study vaccine
- Acute vomiting or diarrhea within 24 hours before the first visit.
- Severely malnourished children (Weight-for-age with z-score < - 3 below the median of
the WHO child growth standards.)
- Previously received 3 doses of OPV or single dose of IPV or OCV at any time before
enrollment based upon immunization card record.
Ages Eligible for Study
1 Year - 3 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. Thus, it is recommended that live-virus vaccines should be administered the same day or ≥4 weeks apart. Data on co-administration of the currently available whole-cell killed Oral Cholera Vaccine (OCVs) with other oral vaccines, specifically, oral polio vaccines (OPV) is lacking. Although the risk of immunological interference due to co-administration of live vaccines with non-live vaccines is considered small if at all, a theoretical concern of interference has been raised. Given the substantial geographic correlation between polio- and cholera-affected and at-risk areas, which include some of the world's most impoverished and hard-to-reach populations, a strategy of co-administration of OCV with OPV to children targeted to receive OPVs has the potential to optimize the use of limited resources and improve coverage for both vaccines. The manufacturer recommendation for a two-week interval between administration of OPV and OCV precludes an integrated campaign or routine use in which OCV could be co-administered with OPV.
Stanford is currently accepting patients for this trial.
Intervention(s):
- biological: Oral Polio Vaccine
- biological: Oral Cholera Vaccine
Eligibility
Inclusion Criteria:
- Apparently healthy children aged 1 to 3 years of age. Family able to understand and
comply with planned study procedures and consents to be in the study.
- Have received either no dose or only one dose of OPV ( 0 - 1 dose) and has not
received any dose of IPV or OCV at any time before enrollment based upon immunization
card record or history from parents.
Exclusion Criteria:
- Parents and children who are unable / unwilling to participate in the full length of
the study for any reason.
- Child / family planning on moving away from the study area during the study period
- A diagnosis, suspicion of, or clinical condition consistent with an immunodeficiency
disorder (either in the child or in a member of the immediate family) or is on
long-term (>3 months) of immunosuppressive therapy.
- A suspicion or known history of bleeding disorder that would contraindicate
venipuncture.
- Acute diarrhea, infection or illness at the time of the first visit that would require
the child's admission to a hospital or would contraindicate provision of OPV per
country guidelines.
- History of severe allergic reaction to component of study vaccine
- Acute vomiting or diarrhea within 24 hours before the first visit.
- Severely malnourished children (Weight-for-age with z-score < - 3 below the median of
the WHO child growth standards.)
- Previously received 3 doses of OPV or single dose of IPV or OCV at any time before
enrollment based upon immunization card record.
Ages Eligible for Study
1 Year - 3 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. Thus, it is recommended that live-virus vaccines should be administered the same day or ≥4 weeks apart. Data on co-administration of the currently available whole-cell killed Oral Cholera Vaccine (OCVs) with other oral vaccines, specifically, oral polio vaccines (OPV) is lacking. Although the risk of immunological interference due to co-administration of live vaccines with non-live vaccines is considered small if at all, a theoretical concern of interference has been raised. Given the substantial geographic correlation between polio- and cholera-affected and at-risk areas, which include some of the world's most impoverished and hard-to-reach populations, a strategy of co-administration of OCV with OPV to children targeted to receive OPVs has the potential to optimize the use of limited resources and improve coverage for both vaccines. The manufacturer recommendation for a two-week interval between administration of OPV and OCV precludes an integrated campaign or routine use in which OCV could be co-administered with OPV.
Stanford is currently accepting patients for this trial.
Intervention(s):
- biological: Oral Polio Vaccine
- biological: Oral Cholera Vaccine
Eligibility
Inclusion Criteria:
- Apparently healthy children aged 1 to 3 years of age. Family able to understand and
comply with planned study procedures and consents to be in the study.
- Have received either no dose or only one dose of OPV ( 0 - 1 dose) and has not
received any dose of IPV or OCV at any time before enrollment based upon immunization
card record or history from parents.
Exclusion Criteria:
- Parents and children who are unable / unwilling to participate in the full length of
the study for any reason.
- Child / family planning on moving away from the study area during the study period
- A diagnosis, suspicion of, or clinical condition consistent with an immunodeficiency
disorder (either in the child or in a member of the immediate family) or is on
long-term (>3 months) of immunosuppressive therapy.
- A suspicion or known history of bleeding disorder that would contraindicate
venipuncture.
- Acute diarrhea, infection or illness at the time of the first visit that would require
the child's admission to a hospital or would contraindicate provision of OPV per
country guidelines.
- History of severe allergic reaction to component of study vaccine
- Acute vomiting or diarrhea within 24 hours before the first visit.
- Severely malnourished children (Weight-for-age with z-score < - 3 below the median of
the WHO child growth standards.)
- Previously received 3 doses of OPV or single dose of IPV or OCV at any time before
enrollment based upon immunization card record.
Ages Eligible for Study
1 Year - 3 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. Thus, it is recommended that live-virus vaccines should be administered the same day or ≥4 weeks apart. Data on co-administration of the currently available whole-cell killed Oral Cholera Vaccine (OCVs) with other oral vaccines, specifically, oral polio vaccines (OPV) is lacking. Although the risk of immunological interference due to co-administration of live vaccines with non-live vaccines is considered small if at all, a theoretical concern of interference has been raised. Given the substantial geographic correlation between polio- and cholera-affected and at-risk areas, which include some of the world's most impoverished and hard-to-reach populations, a strategy of co-administration of OCV with OPV to children targeted to receive OPVs has the potential to optimize the use of limited resources and improve coverage for both vaccines. The manufacturer recommendation for a two-week interval between administration of OPV and OCV precludes an integrated campaign or routine use in which OCV could be co-administered with OPV.
Stanford is currently accepting patients for this trial.
Intervention(s):
- biological: Oral Polio Vaccine
- biological: Oral Cholera Vaccine
Eligibility
Inclusion Criteria:
- Apparently healthy children aged 1 to 3 years of age. Family able to understand and
comply with planned study procedures and consents to be in the study.
- Have received either no dose or only one dose of OPV ( 0 - 1 dose) and has not
received any dose of IPV or OCV at any time before enrollment based upon immunization
card record or history from parents.
Exclusion Criteria:
- Parents and children who are unable / unwilling to participate in the full length of
the study for any reason.
- Child / family planning on moving away from the study area during the study period
- A diagnosis, suspicion of, or clinical condition consistent with an immunodeficiency
disorder (either in the child or in a member of the immediate family) or is on
long-term (>3 months) of immunosuppressive therapy.
- A suspicion or known history of bleeding disorder that would contraindicate
venipuncture.
- Acute diarrhea, infection or illness at the time of the first visit that would require
the child's admission to a hospital or would contraindicate provision of OPV per
country guidelines.
- History of severe allergic reaction to component of study vaccine
- Acute vomiting or diarrhea within 24 hours before the first visit.
- Severely malnourished children (Weight-for-age with z-score < - 3 below the median of
the WHO child growth standards.)
- Previously received 3 doses of OPV or single dose of IPV or OCV at any time before
enrollment based upon immunization card record.
Ages Eligible for Study
1 Year - 3 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. Thus, it is recommended that live-virus vaccines should be administered the same day or ≥4 weeks apart. Data on co-administration of the currently available whole-cell killed Oral Cholera Vaccine (OCVs) with other oral vaccines, specifically, oral polio vaccines (OPV) is lacking. Although the risk of immunological interference due to co-administration of live vaccines with non-live vaccines is considered small if at all, a theoretical concern of interference has been raised. Given the substantial geographic correlation between polio- and cholera-affected and at-risk areas, which include some of the world's most impoverished and hard-to-reach populations, a strategy of co-administration of OCV with OPV to children targeted to receive OPVs has the potential to optimize the use of limited resources and improve coverage for both vaccines. The manufacturer recommendation for a two-week interval between administration of OPV and OCV precludes an integrated campaign or routine use in which OCV could be co-administered with OPV.
Stanford is currently accepting patients for this trial.
Intervention(s):
- biological: Oral Polio Vaccine
- biological: Oral Cholera Vaccine
Eligibility
Inclusion Criteria:
- Apparently healthy children aged 1 to 3 years of age. Family able to understand and
comply with planned study procedures and consents to be in the study.
- Have received either no dose or only one dose of OPV ( 0 - 1 dose) and has not
received any dose of IPV or OCV at any time before enrollment based upon immunization
card record or history from parents.
Exclusion Criteria:
- Parents and children who are unable / unwilling to participate in the full length of
the study for any reason.
- Child / family planning on moving away from the study area during the study period
- A diagnosis, suspicion of, or clinical condition consistent with an immunodeficiency
disorder (either in the child or in a member of the immediate family) or is on
long-term (>3 months) of immunosuppressive therapy.
- A suspicion or known history of bleeding disorder that would contraindicate
venipuncture.
- Acute diarrhea, infection or illness at the time of the first visit that would require
the child's admission to a hospital or would contraindicate provision of OPV per
country guidelines.
- History of severe allergic reaction to component of study vaccine
- Acute vomiting or diarrhea within 24 hours before the first visit.
- Severely malnourished children (Weight-for-age with z-score < - 3 below the median of
the WHO child growth standards.)
- Previously received 3 doses of OPV or single dose of IPV or OCV at any time before
enrollment based upon immunization card record.
Ages Eligible for Study
1 Year - 3 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. Thus, it is recommended that live-virus vaccines should be administered the same day or ≥4 weeks apart. Data on co-administration of the currently available whole-cell killed Oral Cholera Vaccine (OCVs) with other oral vaccines, specifically, oral polio vaccines (OPV) is lacking. Although the risk of immunological interference due to co-administration of live vaccines with non-live vaccines is considered small if at all, a theoretical concern of interference has been raised. Given the substantial geographic correlation between polio- and cholera-affected and at-risk areas, which include some of the world's most impoverished and hard-to-reach populations, a strategy of co-administration of OCV with OPV to children targeted to receive OPVs has the potential to optimize the use of limited resources and improve coverage for both vaccines. The manufacturer recommendation for a two-week interval between administration of OPV and OCV precludes an integrated campaign or routine use in which OCV could be co-administered with OPV.
Stanford is currently accepting patients for this trial.
Intervention(s):
- biological: Oral Polio Vaccine
- biological: Oral Cholera Vaccine
Eligibility
Inclusion Criteria:
- Apparently healthy children aged 1 to 3 years of age. Family able to understand and
comply with planned study procedures and consents to be in the study.
- Have received either no dose or only one dose of OPV ( 0 - 1 dose) and has not
received any dose of IPV or OCV at any time before enrollment based upon immunization
card record or history from parents.
Exclusion Criteria:
- Parents and children who are unable / unwilling to participate in the full length of
the study for any reason.
- Child / family planning on moving away from the study area during the study period
- A diagnosis, suspicion of, or clinical condition consistent with an immunodeficiency
disorder (either in the child or in a member of the immediate family) or is on
long-term (>3 months) of immunosuppressive therapy.
- A suspicion or known history of bleeding disorder that would contraindicate
venipuncture.
- Acute diarrhea, infection or illness at the time of the first visit that would require
the child's admission to a hospital or would contraindicate provision of OPV per
country guidelines.
- History of severe allergic reaction to component of study vaccine
- Acute vomiting or diarrhea within 24 hours before the first visit.
- Severely malnourished children (Weight-for-age with z-score < - 3 below the median of
the WHO child growth standards.)
- Previously received 3 doses of OPV or single dose of IPV or OCV at any time before
enrollment based upon immunization card record.
Ages Eligible for Study
1 Year - 3 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting